JPMorgan has reiterated its overweight rating on Apollo Hospitals, setting a target price of ₹7,200, indicating a 46% upside from the current market price of ₹4,910.20. Apollo’s Q2 results were broadly in line with expectations, supported by continued occupancy strength and healthy revenue growth across its business segments.
The growth was driven by strong occupancy rates, bolstered by healthy increases in both inpatient (IP) and outpatient (OP) volumes. Additionally, Apollo reported an improvement in hospital EBITDA margins, with a notable uptick in the margins of its Apollo Health and Lifestyle Limited (AHLL) segment.
JPMorgan remains positive on Apollo’s outlook, expecting sustained growth momentum driven by strong operational performance.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a financial advisor before making any investment decisions.
